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Elevations in plasma triglyceride are the result of overproduction and impaired clearance
of triglyceride-rich lipoproteins—very low-density lipoproteins (VLDL) and chylomicrons.
Hypertriglyceridemia is characterized by an accumulation in the circulation of large
VLDL-VLDL1–and its lipolytic products, and throughout the VLDL-LDL delipidation
cascade perturbations occur that give rise to increased concentrations of remnant
lipoproteins and small, dense low-density lipoprotein (LDL). The elevated risk of
atherosclerotic cardiovascular disease in hypertriglyceridemia is believed to result from
the exposure of the artery wall to these aberrant lipoprotein species. Key regulators of the
metabolism of triglyceride-rich lipoproteins have been identified and a number of these
are targets for pharmacological intervention. However, a clear picture is yet to emerge as
to how to relate triglyceride lowering to reduced risk of atherosclerosis.
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INTRODUCTION
The metabolism of triglyceride and cholesterol is intertwined because of the shared
physicochemical properties of these molecules. Both need to be transported through the aqueous
medium of blood plasma from sites of production or storage to tissues that require them for
cell functions or energy production. Plasma lipoproteins with their hydrophobic interior and
amphipathic surface provide the means of solubilizing these lipids and facilitating their passage
through the circulation. The fate of the contained lipid is directed by proteins on the particle surface
that interact with key lipolytic enzymes and cell membrane receptors. It is recognized that the levels
of plasma triglyceride and cholesterol in most populations are far in excess of the concentrations
needed to support physiological processes and this leads to pathological consequences such as
atherosclerotic cardiovascular disease (ASCVD) and pancreatitis (1–3). The case for cholesterol-
carrying low-density lipoprotein (LDL) as a causal factor for ASCVD is well made (4, 5) but
until recently there has been significant doubt as to the role of raised plasma triglyceride, carried
in chylomicrons and very-low density lipoproteins (VLDL) (collectively termed triglyceride-
rich lipoproteins, TRL), as a risk factor for the development of atherosclerosis. Epidemiological
studies in the general population consistently demonstrate a strong, positive association of plasma
triglyceride levels with risk of ASCVD (2, 3, 6, 7) but this has been considered confounded, mainly
by the link between higher levels of TRL and decreased concentrations of high-density lipoproteins
(HDL), a lipoprotein class with putative cardio-protective properties (3, 8). A resurgence of interest
in triglyceride as a causative agent for ASCVD and as a possible target for intervention followed
reports that common allelic variations in genes regulating specifically triglyceride metabolism
are associated with differences in cardiovascular disease outcomes (9–11), thus addressing the
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confounding issue, and that lowering plasma triglyceride is
associated with reduced risk of a major cardiovascular event (12)
(but may not be the whole explanation for the benefit seen in
that trial).
Chylomicrons and VLDL have as their major structural
apolipoprotein (apo) B48 and apoB100, respectively. Both TRL
are subject to extensive remodeling during intravascular lipolysis
that leads in the case of chylomicrons to the generation of
“remnants” and for VLDL to a range of products including
remnants within the VLDL density interval, intermediate density
lipoproteins (IDL) and LDL. Given that triglyceride itself is not
found deposited in atherosclerotic plaque, the influence of raised
levels of this lipid on ASCVD is likely to be indirect, that is
through the impact of hypertriglyceridemia on the metabolism
of cholesterol-carrying lipoproteins (5, 13–15), and possibly
also by activation of inflammatory mechanisms (7, 10, 16, 17).
Interventions that lower triglyceride may be understood best, in
terms of their impact on ASCVD risk, in light of the consequent
changes in the entire apoB-containing lipoprotein spectrum. In
this context, it is important to note the findings of a recent
study in which genetic variants that lower plasma triglyceride
were associated with reduced ASCVD risk only when there
was a commensurate decrease in apo B (18). Reduced levels of
high-density lipoprotein (HDL) which are a further consequence
of raised triglyceride levels may contribute to the enhanced
risk (3) but it is unclear whether a change in HDL attendant
on triglyceride lowering will result in decreased CVD risk.
Mendelian randomization studies do not support a causative link
and outcome trials targeting HDL have failed to show a risk
reduction (3, 8, 19).
This review explores the complex interrelationship between
the metabolism of chylomicrons and VLDL, the underlying
causes of hypertriglyceridemia, and the perturbations in this
condition in the structure and metabolism of apoB-containing
lipoprotein species. The aim is to provide a framework that not
only helps in understanding the clinical sequelae of moderate to
severe hypertriglyceridemia but also acts as an aid in interpreting
the results of published (12) and upcoming (20, 21) triglyceride-
lowering outcome trials. For LDL cholesterol (LDLc) lowering
studies, systematic meta-analyses (22) reveal a straightforward
relationship between the absolute reduction in LDLc and the
percent decrease in ASCVD risk—a 22% relative risk reduction
for each 1.0 mmol/l drop in LDLc. With the complexity inherent
in TRL metabolism, it is predictable that the relationship




It is recognized from studies of aboriginal, hunter-gatherer
societies (1–3) and age-related lipid changes in Western
populations (2, 23, 24) that the optimal plasma triglyceride
concentration appears to be in the range below 1.2 mmol/l/l
(<100 mg/dl) (2, 3). In developed countries the average
plasma triglyceride level doubles from early adulthood (mean
triglyceride 0.8 mmol/l at about 20 years) to mid-adult life
(mean of 1.5 mmol/l at about 50 years old) (23, 24). This
rise is driven, at least in part, by the age-related increase
in body weight and adiposity since there is a strong link
between being overweight or obese and higher rates of hepatic
triglyceride synthesis and VLDL secretion (25, 26). Conversely,
weight reduction leads to triglyceride lowering and a decrease
in the production of VLDL (2, 3, 25, 26). Pregnancy is
another physiological condition linked to the development of
hypertriglyceridemia; VLDL levels rise several-fold over the
course of gestation (27, 28), likely as a result of an action of
estrogen on VLDL assembly and secretion (28) in order to
deliver triglyceride to the placenta. In some women, possibly
due to genetic predisposition or a metabolic disorder, frank
hypertriglyceridemia can develop especially during the third
trimester (27, 28).
Accumulation of Large VLDL and
Remnants in Hypertriglyceridemia
Increased levels of plasma triglyceride are associated with the
accumulation of large, triglyceride-rich VLDL-VLDL1–particles
with a diameter range of 50–80 nm containing about 70%
triglyceride by mass. Smaller VLDL-VLDL2–which are 30–
50 nm in diameter and consist of about 30% triglyceride
show a moderate elevation (Figure 1A) (13, 30, 32, 33). The
liver has the capacity to vary the amount of lipid loaded
onto the growing lipoprotein particle in the endoplasmic
reticulum, and indeed depending on triglyceride availability can
assemble and secrete particles that range in size from VLDL1
to LDL (13, 30, 32–35). A number of factors determine the
assembly and secretion rate of apoB100 lipoproteins including
hormone levels, intracellular lipid trafficking, protein regulatory
factors (34, 35), and possibly proprotein convertase/subtilisin
kexin type 9 (PCSK9) (36). VLDL1 synthesis is driven by
the supply of triglyceride from intracellular stores, de novo
lipogenesis, fatty acid uptake, and hepatic chylomicron remnant
removal (37, 38). Overproduction of smaller VLDL2, on the
other hand, is linked to raised cholesterol levels (39) and
is a feature of familial hypercholesterolemia (40, 41). Kinetic
investigations have demonstrated that the metabolic fate of
circulating VLDL particles is a function of their size and lipid
and apoprotein composition (13, 30, 33, 42), especially their apoE
and apoCIII content (42). So, an understanding of the causes
and consequences of hypertriglyceridemia needs to encompass
the factors that govern lipoprotein assembly in the liver and the
enzymes and receptors that regulate flow down the VLDL-LDL
delipidation cascade (Figure 1, main diagram).
As plasma triglyceride rises in the population, metabolic
abnormalities appear throughout the VLDL1-VLDL2-IDL-LDL
delipidation cascade (Figure 1). At triglyceride levels <1.2
mmol/l there are approximately equal amounts of VLDL1 and
VLDL2 in the circulation (inset A) and kinetic studies show
that there is both a low secretion rate and rapid clearance
of VLDL1 (13, 30, 32). As plasma VLDL1 rises due to a
combination of overproduction and less efficient lipolysis, there
is increased metabolic heterogeneity with the appearance of
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FIGURE 1 | Apolipoprotein B 100 metabolic heterogeneity in hypertriglyceridemia. Elevation in plasma triglyceride is associated with an increased concentration of
large VLDL-VLDL1 (A). VLDL1 once secreted from the liver enters a delipidation cascade leading to the formation of smaller VLDL2, IDL, and LDL (main diagram).
Kinetic investigations reveal metabolic heterogeneity within the delipidation pathway. As shown in (B) [taken from Björnson et al. (29)], a tracer of deuterated leucine
administered at time 0 h appears rapidly in VLDL1 and VLDL2. Decay curves in both fractions have an initial rapid phase reflecting lipolysis and a second, slower phase
due to remnant removal. This metabolic heterogeneity (as depicted by the two circles in each lipoprotein class in the main diagram) is more evident as plasma
triglyceride rises (B). For further detail see Packard and Shepherd (13), Björnson et al. (29), Shepherd and Packard (30), and Packard et al. (31).
slowly metabolized species in VLDL1 and VLDL2 (13, 14, 25,
30, 32, 38–43). These products of inefficient VLDL delipidation
are considered “metabolic remnant particles” (Figure 1). They
accumulate in proportion to the increase in plasma triglyceride
(7, 10, 15) and are believed to be able to contribute to the
deposition of cholesterol in atherosclerotic lesions (15, 44) as well
as promote inflammatory processes (16). By way of illustration,
Figure 1B shows the heterogeneity seen in apoB100 metabolism
in VLDL1 and VLDL2 in subjects with low, average, and elevated
plasma triglyceride concentrations [taken from Björnson et al.
(29)]. It can be seen that that once peak enrichment is achieved
at about 2–5 h after injection of the tracer (deuterated leucine),
there is a biphasic log-linear decay indicative of the presence of
at least two metabolically distinct lipoprotein species. The initial
rapid phase is linked to lipolysis while the later, slower decay is
likely attributable to remnant particle clearance. In the group of
subjects with optimal plasma triglyceride, the slow component
was a minor contributor to overall catabolism but in the
groups with higher triglyceride, its contribution in both VLDL1
and VLDL2 became more pronounced. Similar kinetic features
are observed when apoB metabolism is followed in the total
VLDL fraction in hypertriglyceridemic and hypercholesterolemic
subjects (13, 14, 25, 41, 45–47).
Impact of Hypertriglyceridemia on
VLDL-LDL Metabolic Pathways
Heterogeneity in apoB metabolism in hypertriglyceridemia is
not confined to the VLDL density range. In a series of
experiments using radiolabelled lipoproteins as tracers, we
found that when VLDL1 and VLDL2 were isolated, labeled
with alternate iodine isotopes (131I, 125I), and injected into
the donors the metabolism of these two subfractions differed.
There appeared to be “metabolic channeling” within the VLDL-
LDL delipidation pathway (13, 30, 39); that is VLDL1 and
VLDL2 had distinct rates of conversion to IDL and LDL,
and there was variation in the extent of direct catabolism
of remnants from the VLDL1/2 and IDL density intervals as
depicted in the central diagram of Figure 2. This observation
is significant since it implies that the pedigree of an LDL
particle influences its metabolic properties and hence its
potential atherogenicity. Figure 2A shows the appearance and
disappearance curves for LDL derived from VLDL1 and VLDL2
(13). The latter was rapidly and more completely converted
to LDL while lipolysis of the former subfraction generated
less LDL. LDL formed from 125I-VLDL2 (which of course will
include directly secreted VLDL2 and the products of VLDL1
lipolysis) exhibited two catabolic phases; an initially rapid rate
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FIGURE 2 | Apolipoprotein B100 metabolic cascade in hypertriglyceridemia. Plasma triglyceride levels influence the metabolism of LDL as an extension of the
metabolic heterogeneity seen in Figure 1. LDL is derived from the delipidation of VLDL1 but the extent of conversion is less than for VLDL2. The LDL (followed by
virtue of the radioactive label attached to VLDL1 apoB) from VLDL1 has a slow catabolic rate (A). LDL derived from VLDL2 delipidation exhibits a two-phase clearance
curve. The first part represents LDL with a rapid clearance rate (presumably derived from directly secreted VLDL2 ) while the second phase exhibits the same clearance
rate as LDL derived from VLDL1. LDL kinetic studies show a positive relationship between the amount of slowly catabolised LDL produced and the plasma triglyceride
concentration across the “normal range” (B). Plasma triglyceride across the full range of normal through to severe hypertriglyceridemia exhibits a complex relationship
to LDL cholesterol concentration and to LDL fractional catabolic rate (FCR) as shown in (C). Between triglyceride levels of 0.5 to about 3.0 mmol/l FCR falls and LDL
concentration rises due to increased production of VLDL1 which is converted to slowly metabolized LDL. In severe hypertriglyceridemia) (>5.0 mmol/l), LDL FCR is
increased and the concentration decreases due to rapid clearance by stimulated receptor-independent routes (D). (E) Shows the change in LDL size profile as plasma
triglyceride increases. For further detail see Ference et al. (4), Borén et al. (5), Packard and Shepherd (13), Packard et al. (31), and Caslake et al. (48).
followed by much slower decay whereas LDL formed from 131I-
VLDL1 delipidation was catabolized only at the slower clearance
rate (Figure 2A).
The presence of metabolic heterogeneity in the LDL density
range linked to plasma triglyceride levels was examined further
using radiolabelled LDL tracers (31, 48, 49). It was found
that as plasma triglyceride rose across the normal range the
LDL fractional catabolic rate (FCR) fell and LDL concentration
increased until a triglyceride value of about 2–3 mmol/l
(Figure 2C). Above this level the LDL FCR then paradoxically
rose as triglyceride increased, and LDL concentration fell.
This positive association of LDL FCR with the severity of
hypertriglyceridemia has been reported consistently in the
literature (14, 50–53). An explanation that has been offered for
the metabolic heterogeneity depicted in Figures 2A–C is that the
conformation of apoB100 on LDL particles differs depending
on their pedigree (13, 31); in LDL originating from VLDL2/IDL
secreted directly from the liver apoB100 has a conformation that
is able to bind well to LDL receptors and hence the particle
can be catabolized efficiently, whereas LDL derived from VLDL1
delipidation contains apoB100 in which the receptor binding site
is less well-expressed and its clearance is impeded. In analyzing a
series of LDL kinetic studies, we observed a positive relationship
between plasma triglyceride level across the normal range and the
amount of slowly metabolized LDL produced (Figure 2B) (31,
48, 49). This phenomenon potentially explains the fall in overall
LDL FCR as plasma triglyceride rises across the normal range
from 0.4 to 2.0 mmol/l (Inset C). The accelerated catabolism of
LDL in severe hypertriglyceridemics (i.e., at plasma triglyceride
levels above 5 mmol/l in Figure 2C) has been attributed not to
enhanced LDL receptor activity but to stimulation of receptor-
independent pathways (Inset D) (13, 14, 51), possibly involving
the reticuloendothelial system.
LDL Structural Abnormalities in
Hypertriglyceridemia
LDL subfraction distribution is also affected markedly by plasma
triglyceride levels (Figure 2E). It has been shown by a number
of investigators that the concentration of small, dense LDL
(LDL-III) increases significantly when triglyceride rises above
about 1.5 mmol/l and there is a reciprocal drop in LDL-II,
the most abundant subfraction in normal subjects (5, 13, 31,
52, 53). Models for the formation of small, dense LDL link its
metabolic and structural heterogeneity (13, 31, 52, 53). In the
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scheme depicted in Figure 2 [and explained in more detail in
(13, 31)], it is postulated that slowly metabolized LDL derived
from the lipolysis of large VLDL species (VLDL1) has a prolonged
residence time in the circulation and this allows extensive inter-
particle transfer to take place via the agency of cholesteryl
ester transfer protein (CETP). Cholesteryl ester is removed from
the core of LDL particles and replaced with triglyceride from
VLDL donor particles. This compositional change makes LDL
susceptible to hepatic lipase action. This enzyme hydrolyses
surface phospholipid and core triglyceride to generate a smaller
particle. Higher levels of plasma triglyceride, therefore, not
only favor formation of slowly cleared LDL (Figure 2) but also
provide an abundant supply of triglyceride to drive CETP-
mediated exchange. Since small, dense LDL has been proposed
to be more atherogenic than its normal-sized counterpart due
to enhanced binding to arterial wall proteoglycans and its ability
to be oxidized (44, 52–54), this conceptual model provides one
of the key links between variation in plasma triglyceride and
ASCVD risk.
From the above it is clear that elevation in plasma triglyceride
is accompanied by metabolic and structural perturbations
throughout the apoB100-containing lipoprotein spectrum. Since
disadvantageous changes start to be evident as low as 1.5
mmol/l, this has been used as a cut-off for “borderline”
hypertriglyceridemia while “moderate” and “severe” forms of the
condition are defined by plasma triglyceride concentrations in
the range 2.3–5.0 and >5.0 mmol/l, respectively (2, 3). What
is obvious from a consideration of these metabolic patterns is
that hypertriglyceridemia is not a uniform disorder (in contrast
to hypercholesterolemia which is due primarily to a relatively
simple elevation in LDL), rather it is accompanied by a spectrum
of metabolic alterations and the phenotypic presentation will
depend on the activities of a range of key regulatory factors.
GENETIC, HORMONAL AND DIETARY
REGULATION OF PLASMA TRIGLYCERIDE
Some of the most illuminating investigations into the factors
that control VLDL and LDL metabolism have come from the
study of inherited conditions where a specific enzyme, receptor
or cofactor is absent or deficient.
Role of Lipases in Metabolism of
Triglyceride-Rich Lipoproteins
Familial chylomicronemia syndrome, characterized by the
accumulation of extremely high levels of chylomicrons and in
many cases VLDL is the result of inherited deficiencies in key
factors in the pathways of TRL assembly and clearance (55).
One of the best characterized of these disorders is absence
of functional lipoprotein lipase (LpL) activity (2, 3, 55–57) in
which VLDL catabolism is severely impaired, in particular the
lipolysis of VLDL1 (Figure 3) (56, 57). In experiments using
tracers of radio-iodinated VLDL1 and VLDL2 in subjects with the
condition, it was observed that the FCR of VLDL1 was decreased
10-fold but apoB production into this lipoprotein fraction was
similar to normal. VLDL2 clearance, on the other hand, was not
significantly impaired by lack of LpL (57). Deficiency of the other
key lipase in lipoprotein metabolism—hepatic lipase (HL)—is
associated with hypertriglyceridemia but not to the same extent
as seen in LpL deficiency (58–60). Investigations reveal that this
enzyme is more active at hydrolyzing lipid in smaller particles in
the VLDL2, IDL, and LDL density intervals. HL deficient subjects
exhibit reduced clearance rates for VLDL and IDL, and slowed
conversion of VLDL2 to IDL and IDL to LDL (58–60) (Figure 3).
In the subject we studied there was an almost complete inability
to convert IDL to LDL (58).
Lipoprotein Receptors in VLDL Metabolism
The role of the LDL receptor in apoB metabolism was
thought initially to be limited to facilitation of LDL
clearance. However, kinetic investigations in homozygous
familial hypercholesterolemia (FH) indicate that VLDL and
IDL metabolism are affected also (40, 41, 47). While the
production and clearance of the largest VLDL particles—
VLDL1 (Figure 3)—are not altered in homozygous FH, there
is overproduction of VLDL2 [and total VLDL where this was
studied (41)], and delayed clearance of this lipoprotein class, a
reduced IDL FCR, and a very slow conversion of IDL to LDL
(taking an average of 100 h in affected individuals compared
to about 20 h in normal subjects) (40, 47). Understanding the
full contribution of the LDL receptor to apoB metabolism
is important when elucidating the mechanism of action of
drugs that stimulate its activity such as statins and PCSK9
inhibitors (see below). This was explored further in experiments
in which unmodified VLDL subfractions and their chemically
altered counterparts (with blocked arginine resides) which
could not bind to receptors were labeled with the two forms
of radioiodine and administered to normal volunteers (61).
It was observed that modification did not impact on the
kinetics of large VLDL (VLDL1) but delayed the processing
and clearance of a smaller VLDL (VLDL2)/IDL fraction as well
as the catabolism of LDL. These findings suggest again that
the LDL receptor is not involved in VLDL1 metabolism, at
least in normal subjects, but plays a part in the catabolism of
VLDL2 and IDL particles as well as LDL (Figure 3). Since the
modified VLDL2/IDL fraction exhibited a slower conversion
rate to LDL, this was taken as further evidence that the LDL
receptor contributed to this process. The agreement between
these studies and the observations of the metabolic disturbance
in FH where there is an inherited deficiency of LDL receptors is
striking (Figure 3). Direct removal of VLDL1 may be facilitated
by other members of the LDL receptor superfamily which
include LDL receptor related protein 1 (LRP1), the VLDL
receptor, and the apoE-receptor 2 (62, 63). LRP1 is a prime
candidate since it binds apoE and has been implicated in
the hepatic uptake of chylomicron remnants which share
many of the structural features of partially lipolyzed VLDL1
particles (63) (Figure 3).
Role of Apolipoproteins CIII and E in
Metabolism of Triglyceride-Rich
Lipoproteins
Apolipoproteins CII, CIII, and E are small proteins carried
on the surface of lipoproteins that influence their metabolic
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FIGURE 3 | Regulation of apolipoprotein B metabolism by key enzymes, receptors and cofactors. The main diagram depicts the known roles of lipoprotein and
hepatic lipase (LpL, HL); cholesteryl ester transfer protein (CETP); apolipoproteins CII, CIII, and E; LDL receptor (LDL-r). The potential role of the VLDL receptor
(VLDL-r), apoE receptor 2 (apoE-r2), and LDL receptor related protein 1 (LRP1) in VLDL1 removal is speculative. (A) Shows the relative quantitative importance of liver
and body fat in regulating VLDL1 production and of apoCIII in controlling VLDL1 clearance [adapted from (43)]. The numerical values quoted are correlation coefficients.
properties. These apoproteins are not distributed uniformly
and are found in different sub-types of particles within each
density range (42). The metabolism of apoB100-containing
lipoproteins with and without apoCIII and apoE has been
investigated in detail and related to risk of ASCVD (42, 64).
Other studies have delineated the metabolic consequences of
inheriting the various apoE isoforms—apoE2, E3, and E4 (65,
66)—or a deficiency in apoCIII (67–69). In our study of
subjects homozygous for the three apoE protein variants (65)
it was found that those who were E2/2 had a reduced rate
of VLDL1 and VLDL2 direct catabolism indicating delayed
remnant removal, and a marked reduction in the rate of
conversion of IDL to LDL (Figure 3). ApoE isoform type was
a major influence on the extent of conversion of VLDL2 to
LDL; this was 25% in E2/2, 50% in E3/3, and 70% in E4/4
subjects (65). Even a single copy of the apoE4 is sufficient to
influence apoB kinetics leading to an increased VLDL to LDL
conversion and a reduced LDL FCR (66). These observations
help explain why apoE is the most important inherited
trait influencing plasma cholesterol levels, and why in E2/2
individuals with hypertriglyceridemia, remnant lipoproteins
accumulate throughout the VLDL-IDL density range (1–3).
This “remnant” or Type III hyperlipidemia is associated
with accelerated atherosclerosis even though LDL levels are
generally low.
It has long been suspected that apoCIII is a major regulator of
plasma lipid concentrations. Its role in triglyceride transport and
as a potential intervention target has been reviewed recently (67).
Overproduction of apoCIII is associated with raised triglyceride
levels (70), and this apoprotein is a major determinant of
VLDL apoB100 and VLDL triglyceride clearance rates (Figure 3)
(67–72). There appear to be a number of ways in which apoCIII
can influence triglyceride metabolism. It has reported to enhance
VLDL assembly and secretion in the liver, inhibit the action of
lipoprotein lipase and hence slow VLDL lipolysis, and possibly
also retard the direct clearance of VLDL remnants by receptors
(67–72). VLDL particles separated into various sub-types on the
basis of apoprotein content have been shown to be removed
significantly less efficiently from the circulation if they carry
apoCIII (42). Interest in apoCIII as a potential intervention
target was reinforced by the finding that inherited loss-of-
function mutations in this protein were associated with low
plasma triglyceride and a reduced risk of CVD (9–11, 67). Further
exploration of the metabolic consequences of being heterozygous
for apoCIII deficiency (69) gave rise to the observation that
compared to their unaffected siblings, affected subjects had
about half the apoCIII in plasma. VLDL apoB production
was the same both groups (suggesting no impact on VLDL
assembly) but the clearance rate was doubled in carriers of the
apoCIII mutation mainly due to a more efficient VLDL to LDL
conversion rather than stimulation of VLDL direct clearance.
Other proteins including apoA5 (73), Angptl3, Angptl4, and
Angptl8 (74–76) have been identified as important in regulating
lipolysis, and linked to variation in plasma triglyceride and CVD
risk (11).
Impact of Obesity and Hormones on
Triglyceride Metabolism
Secretion of apoB-containing particles from the liver is
governed by the body’s requirements for triglyceride and
Frontiers in Endocrinology | www.frontiersin.org 6 May 2020 | Volume 11 | Article 252
Packard et al. Causes and Consequences of Hypertriglyceridemia
cholesterol in peripheral tissues and the need to regulate
the amount of lipid stored in hepatocytes since pathological
consequences can ensue (such as non-alcoholic fatty liver disease
and hepatosteatosis) when intracellular fat accumulates (77).
Increased VLDL synthesis is present in non-obese and obese
subjects who have high levels of liver fat (25, 26, 32, 38,
78, 79), and we observed positive correlations between the
amount of body fat mass and liver fat with both VLDL1
apoB and VLDL1 triglyceride production rates (Figure 3A)
(43). Likewise, in obese subjects on a weight-loss diet, the
decrease in VLDL secretion rate is related to the fall in liver
fat (25, 26, 79).
Plasma triglyceride concentration across the normal range
and in the hypertriglyceridemic population is (as set out above)
primarily a function of the level of VLDL1 which in turn
is governed by the relative rates of production and clearance
(lipolysis and direct catabolism) of this particle. In a recent
multicenter investigation in which it was possible to include a
large number of subjects with abdominal obesity, the quantitative
contributions of key regulatory factors were assessed in a
statistical model of the determinants of plasma triglyceride (43).
VLDL1 -apoB and -triglyceride kinetic parameters explained
about 70% of the variation in plasma triglyceride and, as depicted
in Figure 3A, significant correlations were found between liver
fat/ body fat mass and the VLDL1 synthesis rate, while the
VLDL1 fractional clearance rate was inversely related to plasma
apoCIII concentration. Lipoprotein and hepatic lipase activities,
and apoCII and apoA5 levels were included in the model but
none of these exhibited a significant association with VLDL1
metabolic parameters. As in earlier analyses, overall it is the
clearance rate that is the dominant feature in regulating VLDL
accounting for about 70% of the variation while production rates
explain around 25% (13, 43).
Hormones associated with glucose and lipid homeostasis
are also important regulatory factors. The presence of insulin
resistance is positively associated with VLDL1 synthesis rates in
both normoglycemic and type 2 diabetic subjects (32, 78–80)
while glucagon acts to suppress VLDL triglyceride release (81).
In contrast, there seems to be no relationship between indices of
insulin resistance or the presence of type 2 diabetes and direct
VLDL2 production (78, 81). In patients with type 2 diabetes,
it can be seen that VLDL- triglyceride and-apoB production
rates were positively related to the extent of hyperglycaemia
(even in well-controlled patients) (78, 79). Further, there was
no difference in particle composition between diabetic and non-
diabetic subjects indicating that the hypertriglyceridemia seen in
type 2 diabetes is associated with the overproduction of VLDL1
particles of normal size and composition. The direct influence
of insulin on VLDL metabolism can be seen also in experiments
in which the hormone was administered acutely to normal and
diabetic subjects (79, 80); the former showed suppression of
VLDL1 (but not VLDL2) production while the latter showed
no such effect (80). These results support the view that VLDL1
and VLDL2 assembly and secretion are independently regulated
in the liver and that the metabolism of VLDL1 due to its role
in triglyceride transport is integrated into whole body energy
homeostatic control.
Impact of Dietary Constituents on
Triglyceride Metabolism
Both quantity and composition of the diet impact on plasma
triglyceride concentrations and can lead to borderline or
moderate hypertriglyceridemia. Excessive intake of calories leads
to storage of triglyceride in adipose and other tissues. Of
particular concern for the regulation of VLDL metabolism is
the accumulation of visceral and liver fat. VLDL synthesis, as
noted above, is driven by the supply of triglyceride to the
lipoprotein assembly pathway in hepatocytes (25, 26, 43, 78,
81, 82). Liver triglyceride is derived from a number of sources,
uptake of fatty acids from the bloodstream (especially that
released from visceral fat depots), release of fatty acids from
stored triglyceride in cytoplasmic lipid droplets, uptake and
hydrolysis of chylomicron remnants, and de novo lipogenesis
(34, 35, 37, 78, 81, 82). These sources can be used variably
by the liver during the course of fasting and feeding cycles.
Of the major dietary constituents, carbohydrate intake seems
to have the greatest impact on plasma triglyceride levels.
Ingestion of a high carbohydrate diet (where carbohydrate
accounts for >55% of energy intake and fat has been reduced
to maintain caloric balance) leads to the development of raised
VLDL due to an increase in VLDL-triglyceride and -apoB
production rates and a decrease in clearance (83). In contrast,
a carbohydrate-restricted diet leads to rapid, beneficial changes
in hepatic lipid metabolism with decreased de novo lipogenesis,
increased fatty acid oxidation, and substantial reductions in
VLDL triglyceride and plasma apoCIII levels (84). Variation in
the type of fat, i.e., replacing saturated fat with monounsaturated
or polyunsaturated fatty acids in the diet also alters plasma
triglyceride and VLDL metabolism but not to the same
extent as replacement of fat with carbohydrate (85). A recent
development in human nutrition has been the incorporation
of increasing amounts of fructose in drinks and foodstuffs.
There is now clear evidence that this sugar has significant
lipogenic properties stimulating hepatic de novo lipogenesis
and liver fat accumulation, and raising triglyceride in the
circulation. Through these mechanisms, excessive consumption
of fructose is linked to development of cardiometabolic disorders
including metabolic syndrome of which hypertriglyceridemia is a
feature (86).
INTEGRATED VIEW OF THE ROLE OF
LIVER AND INTESTINE IN TRIGLYCERIDE
TRANSPORT
For pragmatic as well as theoretical reasons, a great deal of
the research into triglyceride metabolism has been conducted in
the fasted state; “pragmatic” because the VLDL-LDL pathway
arising in the liver is in steady state and can be investigated
using classical kinetic techniques, “theoretical” because the vast
majority of epidemiological surveys linking plasma triglyceride
levels to risk of cardiovascular disease have drawn blood from
subjects fasted overnight i.e., it was VLDL triglyceride that
was measured. However, many researchers over the last three
decades have pointed out that we spend most of our lives
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in the post-prandial state and the contribution of intestine-
derived lipoproteins—chylomicrons and their remnants—to
atherosclerosis must not be ignored (1–3, 10, 15, 87–90).
Reviewing the evidence regarding the association of non-fasting
plasma triglyceride concentrations to CVD risk, it was concluded
by a European expert panel that this parameter was an important
risk factor and possibly superior to assay of fasting levels of the
lipid (91).
Investigating Chylomicron ApoB48 and
VLDL ApoB100 Kinetics
Investigating chylomicron metabolism is a challenge due to
its dynamic nature—these triglyceride-rich lipoproteins appear
as a wave following fat meals—and the need to distinguish it
from very low-density lipoprotein (VLDL) mediated triglyceride
transport. A variety of approaches have been used with varying
degrees of success. Retinyl palmitate has been employed in
the past as a marker of intestinally derived particles (92) but
most kinetic studies now use tracer techniques to assess apoB48
kinetics (since this form of apoB is found solely in particles
of intestinal origin: apoB100 in VLDL is exclusively liver-
derived) (92–98). However, the low abundance of apoB48 and
its transient behavior have presented challenges in the conduct
and interpretation of kinetic studies. Some investigators have
addressed these issues by employing quasi-steady-state designs
with participants fed micro-meals across the day (93, 94, 97)
others by the use of simplified kinetic analysis (95) but neither
of these approaches replicates the physiological situation of the
overlay of a complex, non-steady state process—post-prandial
lipid absorption—on the relatively constant VLDL pathway.
Using the continuous feeding protocol, it was found that the
production rate of apoB48 in normal subjects was about 70 mg/d
which is relatively minor compared to the 500–1,200 mg/d for
apoB100 in VLDL1 (93, 94, 97). To put this in the context of
triglyceride mass transport, it can be estimated that the intestine
presented with these small meals processes and releases ∼90 g
of triglyceride per day in the form of chylomicrons (given an
average dietary intake of fat) whereas the liver secretes in the
region of 25 g/d of VLDL1-triglyceride (13, 25, 33, 43). Since
apoB48 has a molecular weight that is half that of apoB100,
the production rate in mg/d can be doubled to get an idea
of the relative number of particles released from both organs.
Further, chylomicrons with diameters in the 100–200 nm range
are able to accommodate much more triglyceride per particle
than VLDL1 and this provides the necessary capacity for the
intestine to handle the substantial amount of lipid taken up
during absorption of a fat meal. The overall fractional clearance
rate for apoB48 was of the order of 4 pools/d (93–95, 97) which is
lower than that seen for VLDL1 at 5–15 pools/d indicating that
while chylomicrons are the preferred substrate for lipoprotein
lipase and hence hydrolysis of their core triglyceride is rapid,
removal of the resultant remnant apoB48 particle is relatively
slow compared to VLDL1 clearance.
Integrated Regulation of Chylomicron and
VLDL Metabolism
Adopting a more physiological feeding pattern in which a fat-
rich meal is consumed and the resultant peak of alimentary
lipaemia quantified either by measuring retinyl palmitate as
tracer or quantifying apoB48 plasma levels, it was observed that
triglyceride levels rose over 2–6 h in normal subjects and then
returned to near fasting concentration by about 10 h (92, 96). In
subjects with hypertriglyceridemia, the peak of chylomicronemia
is higher and it takes much longer for the wave of particles to
be cleared from the circulation and apoB48 to return to baseline
(2, 3, 7, 92, 96). It has been observed that apoB48 is present in
plasma after an overnight fast (before any food is ingested) in
an amount that is proportional to the plasma triglyceride level
(92, 96, 98). These findings indicate either that the intestine
releases lipoproteins containing apoB48 on a continuous basis
or that apoB48 remnant particles persist for much longer in the
circulation than previously thought (29, 94, 95, 98). The latter
possibility was investigated in a recent study in which plasma
apoB concentration was monitored over a prolonged fast and it
was seen in hypertriglyceridemic subjects that it was many hours
before apoB48 reached a nadir (29, 98). Another feature of apoB
metabolism is the finding that when apoB48 is measured across
the whole size range of triglyceride-rich lipoproteins following
a dietary fat load, it appears in the VLDL1 and VLDL2 density
intervals in about the same timeframe as in chylomicrons (92, 96–
98) either as a result of rapid lipolysis or by direct secretion from
the intestine, that is enterocytes not only release VLDL sized
particles in the fasted state but also at an augmented rate during
fat absorption.
With the advent of more sensitive mass spectrometry
techniques it has become possible to explore apoB48 kinetic
behavior in much greater detail than before. By following
the metabolism of trace-labeled apoB48 and apoB100 in
chylomicrons and VLDL following a fat-rich meal, we have
been able recently to build an integrated picture of the
metabolism of liver and intestinally-derived triglyceride-rich
lipoproteins during fat absorption, as depicted in Figure 4. Key
findings were that in subjects with borderline to moderate
hypertriglyceridemia, apoB48 metabolism was significantly
perturbed. There was a low level of basal apoB48 direct secretion
(prior to the fat meal) into the VLDL1 and VLDL2 density ranges
and this increased several-fold post-prandially (Figure 4). This
indicates that, indeed, the intestine assembles and secretes VLDL
throughout the day—fasted or fed—and this pathway contributes
significantly to circulating TRL found in the VLDL1 and VLDL2
density ranges. It was estimated that in subjects with raised
triglyceride (>2 mmol/l) apoB48 secretion into VLDL was ∼600
nmol/d compared to 2,200 nmol/l for apoB100, and across the
day apoB48-containing lipoproteins accounted for about 25% of
VLDL particles (29). It is known that chylomicrons and VLDL
compete for the same lipolytic mechanism with the former being
preferred. When chylomicrons appear, apoB100 levels in VLDL
have been shown to rise sharply (29, 92, 97, 98) (Figure 4A).
We were able to account satisfactorily for the rise in VLDL1-
apoB100 by including an inhibitory action of chylomicrons on
VLDL1 clearance; the VLDL1-apoB100 FCR fell transiently by
an average of 60% (Inset A) and then returned to pre-meal
levels once chylomicrons were cleared. Thus, it appears that not
only does the intestine contribute more than previously thought
to circulating TRL found in the VLDL density range, but also
that the release of chylomicrons impacts on the metabolism of
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FIGURE 4 | Impact of alimentary lipemia on apolipoprotein B metabolism hypertriglyceridemia. The intestine can secrete chylomicrons, and particles in the VLDL
density range during lipid absorption. The appearance of chylomicrons in the circulation impairs VLDL1 lipolysis as shown in (A). In an integrated multi-compartmental
model, following a fat meal, VLDL1 apoB100 concentration increased and this was attributed to a drop in VLDL1 to VLDL2 transfer (i.e., reduced lipolysis rate) (29, 98).
High density lipoprotein (HDL) via the agency of cholesteryl ester transfer protein (CETP) can transfer cholesteryl ester (CE) to triglyceride-rich lipoproteins thereby
increasing their cholesterol content.
liver-derived VLDL, slowing its clearance from the bloodstream
(as depicted by the dashed arrow in Figure 4) and thereby
favoring remnant generation. Clearance rates of both apoB48 and
apoB100 particles in VLDL1 and VLDL2 were retarded markedly
in hypertriglyceridemic subjects with residence times rising from
1 to 4 h in individuals with low triglyceride (<1.2 mmol/l) to
4–13 h in those with triglyceride >2 mmol/l (29). It follows,
therefore, that both liver and intestine are responsible for the
generation of long-lived remnant particles that could promote
atherogenesis in hypertriglyceridemic subjects.
MECHANISTIC INSIGHTS FROM
PHARMACOLOGICAL INTERVENTIONS
Further insight into the factors that regulate triglyceride
transport comes from clinical trials in which lipid-lowering drugs
have been shown to alter the metabolism of apoB100 and B48 in
subjects with elevated plasma triglyceride levels (Figure 5).
Insights From the Mechanism of Action of
Fibrates and Fish Oil
Fibrates reduce plasma triglyceride levels—both in VLDL and
chylomicrons—principally by increasing the FCR of VLDL (50,
99–105), especially that of the VLDL1 subfraction (102, 105)
and reducing the extent of alimentary lipemia (100). This is
likely due to the action of the drug on the PPARα response
element within the apoCIII gene promoter region that results
in decreased expression of the protein (1–3, 50, 100, 101)
and, as a consequence, enhanced activity of lipoprotein lipase.
Acceleration of VLDL transfer down the delipidation cascade
may, in line with the findings in apoCIII deficiency states (67–
69), be the main effect of fibrates on apoB metabolism but in
those with elevated triglyceride levels direct removal of VLDL
particles may become quantitatively important (Figure 1) and
fibrate-induced changes in apoCIII levels on particles may alter
this pathway also (42). However, we observed that bezafibrate
therapy in hypertriglyceridemics increased the amount of smaller
VLDL (VLDL2) particles in the circulation (102, 105) due to the
fact that clearance of these species was not stimulated by the drug.
In individuals with initially low plasma triglyceride,
fenofibrate therapy caused LDL cholesterol and apoB
concentrations to fall by 10–20% (49, 50, 105) due to an
increased clearance rate. Further exploration of the changes
in LDL metabolism led to the finding that on fenofibrate
the production rate of slowly metabolized LDL (Figure 2)
was reduced and that of rapidly metabolized LDL enhanced
(49, 105). Thus, the observation that in subjects with borderline
hypertriglyceridemia and raised LDL cholesterol, fenofibrate
therapy increased overall LDL clearance was understood better
in terms of this shift in the pedigree of LDL particles, possibly
attributable to the drug-induced alterations in the metabolism
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FIGURE 5 | Mechanistic insights from pharmacological interventions. The diagram shows the known and putative actions of fibrates/selective peroxisome proliferator
receptor α modulators (SPPARαM); fish oils (Omega-3 FA); statins; PCSK9 inhibitors (PCSK9i).
of VLDL1, the source of slowly cleared LDL (Figure 2). In
severe hypertriglyceridemia, fibrates correct partially the
hypercatabolism of LDL (Figures 2C,D) and LDL concentration
increases by 20–30% (49–51). The decrease in clearance rate
has been attributed to less active receptor-independent catabolic
pathways (51, 105). Structural changes in LDL accompany
these metabolic perturbations with fibrate therapy being
associated with an increase in larger sized LDL subfractions
(99–101, 104–106).
Omega-3 fatty acids [eicosapentaenoic (EPA) and
docosahexanoic (DHA) acids and their derivatives] given
in high doses (>2 g/d) lower VLDL in proportion to the dose
given and the basal plasma triglyceride level; reductions vary
from 20% in moderate hypertriglyceridemia to about 35% in
those with more severely elevated levels (1–3, 85, 107, 108).
Kinetic investigations show consistently that high dose fish
oils reduce the production of VLDL triglyceride and apoB (i.e.,
decrease particle secretion rates) (Figure 5) without altering the
overall fractional clearance rate of this lipoprotein, a mechanism
of action that is clearly distinct from that of fibrates (108–112).
The decrease in synthesis and secretion of VLDL on omega-3
fatty acid supplementation has been linked in animal models
with decreased hepatic lipogenesis, stimulation of mitochondrial
fatty acid oxidation in the liver (108, 109, 112) and enhanced
degradation of apoB in the endoplasmic reticulum (112).
LDL levels have been reported to be variably affected by
fish oil supplementation. LDL cholesterol exhibits usually no
change or a modest increase in individuals with moderate
hypertriglyceridemia but in severe hypertriglyceridemia, a
substantial rise in LDL cholesterol in the order of 30% can
occur (similar to the response to fibrates) (108). Investigators
have found repeatedly that the extent of VLDL to LDL
conversion is increased on fish oil (85, 108, 111, 113). The
reason for this is unknown but is possibly not due to a
change in overall lipolytic capacity since there is no change
in VLDL fractional catabolic rate. Fish oils have been reported
to have variable effects on lipase activity, and at least in
hypertriglyceridemic subjects there appears to be no increase
in lipoprotein lipase measured as heparin-releasable enzyme
(112). A reduction in plasma levels of apoCIII has been seen
in severe hypertriglyceridemic subjects given omega-3 fatty
acids (112) and this may influence the lipolytic potential of
both VLDL1 and chylomicrons (Figures 3, 4) but again, in
contrast to the fibrate mechanism of action, an increase in
VLDL FCR would have been expected if this was a rate-
limiting factor. Another explanation along the lines of the
concept depicted in Figure 2, is that fish oils by decreasing
triglyceride availability for VLDL assembly favor the release of
smaller VLDL which is more efficiently converted to the lipolytic
products IDL and LDL. There have been few experiments
looking at the metabolism of VLDL subfractions on fish oil.
However, observations supporting this hypothesis come from a
small study in patients with diabetes that found that omega-
3 fatty acid supplementation (1.8 g/d EPA) led to a specific
decrease in VLDL1 triglyceride concentration due to decreased
synthesis. There was no change in VLDL2 triglyceride level or the
kinetics of this particle while the direct production of IDL was
increased (113).
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Insights From the Mechanism of Action of
Statins and PCSK9 Inhibitors
It has been recognized for some time that statins have the
capacity to reduce plasma triglyceride concentrations to a modest
degree in individuals with normal triglyceride levels and more
substantially in those with elevated concentrations. A “rule-of-
thumb” has emerged that in hypertriglyceridemic subjects, the
percentage reduction in plasma triglyceride equals that of LDL
cholesterol (114). Metabolic studies investigating the mechanism
by which statins lowered VLDL in hypertriglyceridemic subjects
revealed that the drug stimulated the fractional clearance
rates of all apoB-containing lipoproteins from VLDL1 through
to LDL (115–118). These observations are consistent with
the concept that receptors, especially the LDL receptor,
play a critical role in catabolism of lipoproteins across
the VLDL-LDL metabolic cascade as depicted in Figure 3.
VLDL1 direct catabolism does not seem to involve the LDL
receptor pathway (Figure 3) and yet it was accelerated in
subjects on statin therapy. A possible explanation is that
another lipoprotein receptor, regulated by cellular cholesterol
in a manner similar to the LDL receptor is stimulated
by statins in hypertriglyceridemic subjects (Figure 5). One
possibility is LRP1 which is reported to be upregulated by
statins (119).
Evidence from clinical trials indicates that reduction in
plasma triglyceride and VLDL on PCSK9 inhibitors occurs but
is less marked than that seen when a statin is given, even
when the drugs are used as monotherapy (118, 120, 121).
Kinetic studies conducted to date show small changes if any in
VLDL apoB metabolism when PCSK9 inhibitors are added to
background statin therapy or used alone (118, 120); the most
notable perturbation is a modest increase in VLDL apoB FCR.
Exploration of the action of PCSK9 inhibitors on chylomicron
metabolism shows a lack of effect on the post prandial rise in
triglyceride following a fat meal challenge, and on the increment
in apoB48 levels (118, 121). However, these investigations were
conducted in subjects with low or normal plasma triglyceride
and it might be expected that the response would be more
marked in subjects with raised plasma triglyceride (as for statins).
In a recent study in patients with diabetes, it was observed
that plasma triglyceride was reduced about 15% (122), and we
saw a similar, small but significant drop in diabetic patients
with borderline raised triglyceride treated with evolocumab
that was accompanied by a decrease in apoCIII, a reduced
post-prandial rise in triglyceride, a 29% decrease in remnant
cholesterol, and a 17% lower increment in apoB48 following
a standard fat meal (123). We found further that evolocumab
appeared to have a significant impact on the fasting triglyceride
concentration in VLDL2 (23% decrease, P < 0.001) but not
in VLDL1. A tentative interpretation of this unusual finding—
normally when triglyceride is lowered the effect on VLDL1 is
greater than that on VLDL2–is that PCSK9 inhibitors do not
impact on the activity of LRP1 (Figure 5) since this receptor
lacks the binding motif for PCSK9 and so is not regulated by
this protein (62), but VLDL2 removal by the LDL receptor
is stimulated.
CONCLUSIONS
The potential benefits for cardiovascular disease prevention of
triglyceride lowering were equivocal in trials of both fibrates
and omega-3 fatty acids, at least prior to REDUCE-IT (1–
3, 12, 100, 108). This was attributed to either the possibility
that the target—triglyceride rich lipoprotein—was not part
of the causal pathway, or that the wrong patient phenotype
had been selected, or that the agents did not have sufficient
impact on correcting the underlying dyslipidaemia. With the
positive results of the first large-scale outcome trial to focus
on hypertriglyceridemic subjects (12), and the persistent post-
hoc observation that individuals with a phenotype of raised
triglyceride and low HDL cholesterol do appear to benefit in
terms of relative risk reduction in the major fibrate trials (3),
it may be that triglyceride-lowering to be effective needs to
be deployed in people with the hypertriglyceridemia-driven
disturbances in apoBmetabolism described in this review. This is
true also when triglyceride reduction is used as added treatment
on top of statin therapy since the association with risk persists
even though LDL cholesterol levels are well-managed (124, 125).
It is clear that in the hypertriglyceridemic state abnormalities
exist in a number of metabolic pathways and that elevation in
triglyceride levels is accompanied by perturbations throughout
the VLDL1-VLDL2-IDL-LDL delipidation cascade. Deciphering
the quantitative relationship between drug (or diet)—induced
decrease in plasma triglyceride and reduced risk of ASCVD,
as has been elegantly done for the much simpler case of
LDL cholesterol lowering, may prove challenging. If the critical
change is in the circulating concentrations of VLDL remnants,
chylomicron remnants, and specific LDL subfractions (Figure 2)
then better analytical measures are needed to quantify these
lipoprotein species. Finally, it is recognized increasingly that the
size of the unmet clinical need is substantial in the “real-world”
where surveys have revealed a high prevalence of persistent
hypertriglyceridemia in well-treated patients with established
ASCVD (126), and in patients with diabetes and metabolic
syndrome (127, 128).
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